Oncolytics Biotech Inc.
ONC.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 18.15% | -31.95% | -3.70% | -76.17% | 60.77% |
| Total Depreciation and Amortization | -25.71% | 7.54% | -21.49% | 16.03% | 2.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 253.15% | 134.66% | 118.37% | 82.38% | -3,309.86% |
| Change in Net Operating Assets | -121.67% | 1,914.26% | 741.22% | -102.18% | -59.06% |
| Cash from Operations | -58.21% | 28.91% | 10.05% | -23.07% | -0.12% |
| Capital Expenditure | 81.70% | 79.26% | -232.26% | -1,450.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Investing | 81.70% | 79.26% | -232.26% | -1,450.00% | -100.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -25.00% | -23.08% | 36.89% | 0.96% | -1.96% |
| Issuance of Common Stock | 1,157.14% | -86.78% | 30.08% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 55.53% | -190.08% | -84.51% | -102.60% | 212.68% |
| Cash from Financing | 1,981.15% | -108.79% | 30.16% | -13.39% | -91.93% |
| Foreign Exchange rate Adjustments | 488.45% | -187.65% | -65.91% | 204.89% | -254.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 32.18% | -10.86% | 11.79% | -5.69% | -122.25% |